Navigation Links
NIH launches Phase I clinical trial of novel drug to treat Clostridium difficile infection
Date:7/9/2014

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has launched an early-stage clinical trial of CRS3123, an investigational oral antibiotic intended to treat Clostridium difficile (C. difficile) infection. CRS3123 (previously known as REP3123) is a narrow-spectrum agent that inhibits C. difficile growth while sparing normal intestinal bacteria.

The Phase I trial will enroll up to 30 healthy men and women ages 18 to 45 in a dose-escalation study to evaluate the investigational drug's safety and tolerability. Quintiles, through Dynport Vaccine Company, is conducting the study of CRS3123. The medication is being provided by its developer, Crestone, Inc., a pharmaceutical company based in Boulder, Colo.

C. difficile infection affects the digestive track with manifestations ranging from mild diarrhea to life-threatening colitis. Infection most commonly affects patients in hospitals or long-term care facilities and people who have taken antibiotics. Each year, roughly 250,000 people in the United States require hospital care for C. difficile infection and at least 14,000 people die from the infection, according to the U.S. Centers for Disease Control and Prevention (CDC). As a result, the CDC identified C. difficile as an urgent public health threat in its 2013 report on antibiotic resistance. Resistance to the antibiotics currently used to treat C. difficile is not yet a problem, but the bacteria spreads rapidly because it is naturally resistant to many drugs used to treat other infections. Recurrent infections pose a particular clinical challenge, especially those caused by a newer, stronger C. difficile strain, which result in up to 25 percent of patients needing additional therapy.

In the new clinical trial, participants will be randomly assigned into three groups of 10 participants each (8 participants will receive the inves
'/>"/>

Contact: Jennifer Routh
jennifer.routh@nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
Source:Eurekalert  

Page: 1 2

Related medicine news :

1. IntegraGen launches ARISk test, a genetic screening tool for autism in high-risk children
2. Mayo Clinic launches whole genome breast cancer study
3. Original research papers on acute cardiovascular care: ESC launches EHJ-ACVC
4. UCLA launches first face transplantation program in western US
5. Georgia Tech launches HomeLab to help companies evaluate home health technologies
6. US Drug Watchdog Launches Now Calls Transvaginal Mesh A Disaster For 100,000's of US Women Recipients And Offers The Names and Contacts Of The Best Women Attorneys
7. K9 CarFence™ Launches as Newest Innovation in Pet Transportation
8. Golden Gate Opportunity: Moravia Worldwide Launches Bay Area Operation
9. 'Music Makes It Better' Campaign Launches with Justin Bieber, Victoria Justice, and The Band Perry
10. Fieldtex Products Launches a New Wellness Rewards Service for Companies
11. Recruiting for Good Launches Pet Philanthropy Program to Collaboratively Fundraise for Kitt Crusaders an Animal Rescue Organization
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
NIH launches Phase I clinical trial of novel drug to treat Clostridium difficile infection
(Date:4/1/2015)... (PRWEB) April 01, 2015 New ... joined by other First Spouses from across the ... on March 21, 2015, World Down Syndrome Day(WDSD), ... the rapidly advancing area of Down syndrome cognition ... states included Alabama, Alaska, American Samoa, Arizona, California, ...
(Date:4/1/2015)... Altamonte Springs, FL (PRWEB) April 01, 2015 ... the nation’s leading innovative specialty pharmacies, has released a ... the latest treatment guidelines for treating chronic hepatitis C ... up-to-date treatment guidelines based on information from the American ... other credible, scientific sources. , Numerous new direct-acting oral ...
(Date:4/1/2015)... 01, 2015 Dr Roz Kamani, a ... is now offering her patients an opportunity to learn ... participate in “Beauty Days”, which is an exclusive VIP ... Kamani’s Kitsilano Skin Care Clinic. It is attended by ... about the latest products and services that are on ...
(Date:4/1/2015)... April 01, 2015 South Florida’s newest ... Certificate of Authority (PCOA) approval from the State of ... the ongoing development of a retirement community that will ... wellness and spiritual development. , America’s aging population is ... the housing needs of seniors, according to a recent ...
(Date:4/1/2015)... 01, 2015 Health Advocate™, Inc., the ... subsidiary of West Corporation, today launched its new Health ... and through the Health Advocate member website, features ... and stay, healthy. , “We’re pleased to introduce this ... public,” said Martin Rosen, Executive Vice President, Health Advocate. ...
Breaking Medicine News(10 mins):Health News:Governor First Spouses Join with New Jersey First Lady Mary Pat Christie to Support Advances in Biomedical Research to Treat Down Syndrome Cognitive Impairment 2Health News:BioPlus Specialty Pharmacy Releases ‘HCV Treatment Path’ App for Hepatitis C Providers 2Health News:Dr Roz Kamani Now Offers Patients The Opportunity to Learn About Latest Products and Services 2Health News:Casa Sant’Angelo Receives Approval for New Retirement Living 2Health News:Health Advocate Launches New Health and Wellness Blog 2
... assistance from the San Diego Supercomputer Center at UC ... creation of customized therapies for virulent flu strains that ... this week in Nature Communications , could aid ... ,pockets., Using powerful computer simulations on SDSC,s new ...
... at the University of Washington (UW) in Seattle have ... The achievement opens new possibilities for molecular medicine researchers ... epilepsy, and heart rhythm disturbances. Sodium channels are ... as brain nerve cells or beating heart cells ...
... July 13 (HealthDay News) -- For patients taking the heart ... not cause more incidents of thyroid dysfunction than the brand-name ... there is no difference between the two drugs, according to ... Medical Association Journal) . Amiodarone, a drug used to ...
... A study published in the July issue of ... among hypertensive patients with coronary artery disease, chronic self-reported ... an increased risk of adverse events during long-term follow-up. ... pain. Researchers from the Division of Cardiovascular Medicine, ...
... In a result that will fundamentally change approaches to ... that individuals at high risk for HIV infection who ... either the antiretroviral medication tenofovir or tenofovir in combination ... those who received a placebo pill. These findings are ...
... Reinberg HealthDay Reporter , TUESDAY, July 12 ... make getting dental care difficult for children and adolescents ... Sandra L. Decker, senior service fellow in the ... for Disease Control and Prevention, found that in states ...
Cached Medicine News:Health News:UC Irvine study points to new approach to influenza's antiviral resistance 2Health News:Atomic structure discovered for a sodium channel that generates electrical signals in living cells 2Health News:Atomic structure discovered for a sodium channel that generates electrical signals in living cells 3Health News:Atomic structure discovered for a sodium channel that generates electrical signals in living cells 4Health News:Generic, Brand-Name Heart Drugs Seem to Have Same Effect on Thyroid 2Health News:Long-term NSAID use by hypertensive patients with CAD increases risk of adverse events 2Health News:Pivotal study in Africa finds that HIV medications prevent HIV infection 2Health News:Pivotal study in Africa finds that HIV medications prevent HIV infection 3Health News:Dental Care for Kids on Medicaid Varies by Fees Each State Sets 2Health News:Dental Care for Kids on Medicaid Varies by Fees Each State Sets 3
(Date:4/1/2015)... LAVAL, Quebec , April 1, 2015 ... Salix "), a wholly owned subsidiary of Valeant Pharmaceuticals ... that it today provided a Notice of Fundamental Changes, ... Notice, Notice of Execution of Supplemental Indenture and Offer ... its 1.5% Convertible Senior Notes due 2019 (the " ...
(Date:4/1/2015)... BEDFORD, Mass. , April 1, 2015  Hologic, ... has notified holders of the 2.00% Convertible Exchange Senior ... 23, 2010, and Wilmington Trust Company, the trustee, paying ... are eligible to convert the notes.  This conversion right ... governing the notes dated as of December 10, 2007, ...
(Date:4/1/2015)...  The first national study to look at ... attention-deficit/hyperactivity disorder (ADHD) among children ages 4-17 shows ... ADHD were receiving behavioral therapy in 2009-2010 . ... (CDC) study, "Treatment of Attention-Deficit/Hyperactivity Disorder among Children ... The Journal of Pediatrics provides a ...
Breaking Medicine Technology:Salix Provides Notice of Fundamental Changes, Make-Whole Fundamental Changes and Merger Event Relating to Its 1.5% Convertible Senior Notes Due 2019 2Salix Provides Notice of Fundamental Changes, Make-Whole Fundamental Changes and Merger Event Relating to Its 1.5% Convertible Senior Notes Due 2019 3Salix Provides Notice of Fundamental Changes, Make-Whole Fundamental Changes and Merger Event Relating to Its 1.5% Convertible Senior Notes Due 2019 4Salix Provides Notice of Fundamental Changes, Make-Whole Fundamental Changes and Merger Event Relating to Its 1.5% Convertible Senior Notes Due 2019 5Salix Provides Notice of Fundamental Changes, Make-Whole Fundamental Changes and Merger Event Relating to Its 1.5% Convertible Senior Notes Due 2019 6Salix Provides Notice of Fundamental Changes, Make-Whole Fundamental Changes and Merger Event Relating to Its 1.5% Convertible Senior Notes Due 2019 7Hologic Delivers Notice that Holders of 2.00% Convertible Exchange Senior Notes Due 2037 are Eligible to Convert 2CDC publishes first national study on use of behavioral therapy, medication and dietary supplements for ADHD in children 2CDC publishes first national study on use of behavioral therapy, medication and dietary supplements for ADHD in children 3CDC publishes first national study on use of behavioral therapy, medication and dietary supplements for ADHD in children 4
... www.ecardio.com ) announces three executive appointments in an effort to ... patients they serve. "The continued growth that eCardio ... an opportunity to expand the roles of three members of ... Executive Officer. Robert Jordan, Executive Vice President, will ...
... 2011 Inovio Pharmaceuticals, Inc. (NYSE Amex: ... and preventive vaccines against cancers and infectious diseases, announced ... and electroporation delivery technology at the 14th Annual Meeting ... to be held May 18-21 in Seattle, Washington at ...
Cached Medicine Technology:Inovio Pharmaceuticals to Present at American Society of Gene & Cell Therapy Annual Meeting May 18 - 21, 2011 2Inovio Pharmaceuticals to Present at American Society of Gene & Cell Therapy Annual Meeting May 18 - 21, 2011 3Inovio Pharmaceuticals to Present at American Society of Gene & Cell Therapy Annual Meeting May 18 - 21, 2011 4
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: